Abbott Laboratories (NYSE:ABT) Coverage Initiated at Benchmark

Investment analysts at Benchmark assumed coverage on shares of Abbott Laboratories (NYSE:ABT) in a report issued on Friday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $145.00 price target on the healthcare product maker’s stock. Benchmark’s target price would indicate a potential upside of 9.60% from the company’s previous close.

Other equities research analysts have also recently issued reports about the company. Weiss Ratings reissued a “buy (b)” rating on shares of Abbott Laboratories in a research note on Wednesday. William Blair raised Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, July 17th. BTIG Research cut their target price on Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating on the stock in a research note on Friday, July 18th. Leerink Partnrs raised Abbott Laboratories to a “hold” rating in a research report on Monday, June 16th. Finally, Wells Fargo & Company dropped their price objective on Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating on the stock in a research report on Friday, July 18th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $146.17.

Abbott Laboratories Price Performance

ABT opened at $132.30 on Friday. Abbott Laboratories has a 12-month low of $110.86 and a 12-month high of $141.23. The company has a market cap of $230.26 billion, a price-to-earnings ratio of 16.58, a price-to-earnings-growth ratio of 2.51 and a beta of 0.69. The stock has a fifty day simple moving average of $132.54 and a two-hundred day simple moving average of $131.60. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting analysts’ consensus estimates of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.01 billion. During the same period in the prior year, the firm posted $1.14 earnings per share. The company’s quarterly revenue was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the firm’s stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.46% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ABT. Charles Schwab Trust Co lifted its position in shares of Abbott Laboratories by 109.8% during the 3rd quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock valued at $3,939,000 after buying an additional 15,394 shares in the last quarter. Sound Income Strategies LLC lifted its position in shares of Abbott Laboratories by 9.6% during the 3rd quarter. Sound Income Strategies LLC now owns 1,995 shares of the healthcare product maker’s stock valued at $266,000 after buying an additional 175 shares in the last quarter. Thomasville National Bank lifted its position in shares of Abbott Laboratories by 24.9% during the 3rd quarter. Thomasville National Bank now owns 21,264 shares of the healthcare product maker’s stock valued at $2,848,000 after buying an additional 4,240 shares in the last quarter. Foster Victor Wealth Advisors LLC lifted its position in shares of Abbott Laboratories by 2.6% during the 3rd quarter. Foster Victor Wealth Advisors LLC now owns 3,775 shares of the healthcare product maker’s stock valued at $508,000 after buying an additional 94 shares in the last quarter. Finally, Orrstown Financial Services Inc. lifted its position in shares of Abbott Laboratories by 2.9% during the 3rd quarter. Orrstown Financial Services Inc. now owns 8,025 shares of the healthcare product maker’s stock valued at $1,075,000 after buying an additional 228 shares in the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.